<DOC>
	<DOC>NCT01762280</DOC>
	<brief_summary>Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Famitinib in patients with solid tumor</brief_summary>
	<brief_title>A Phase I Study of Famitinib Malate in Patients With Solid Tumor</brief_title>
	<detailed_description>1. To evaluate the safety and tolerability of Famitinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). 2. To determine the pharmacokinetic profile of Famitinib and its metabolites . 3. To assess preliminary antitumor activity . 4. To determine preliminary dose and regimen for phase II study .</detailed_description>
	<criteria>Histological confirmed advanced or metastatic solid tumor，at least one measurable lesion, larger than 10 mm in diameter by spiral CT scan(scanning layer ≤ 5 mm ) no standard therapy protocol available according to patients'condition both sex, age 18 to 65 ECOG 01 Life expectancy more than 3 months ALT,AST,TB≤1.5(UNL),normal serum creatinine level, normal electrolyte or can be corrected by medication Subjects receiving damage caused by other therapeutic has been restored, the interval more than six weeks since the last receiving nitroso or mitomycin; more than 4 weeks since last receiving radiotherapy, other cytotoxic drugs or surgery Understand and agree to sign informed consent form. Peripheral neuropathy ≥ Grade 2(according to NCICTC 3.0) Preexisting uncontrolled hypertension defined as more than 140/90 mmHg by using single agent therapy, ＞Grade 1 (NCICTCAE 3.0 ) myocardial ischemia, arrhythmia,cardiac function insufficiency PT, APTT, TT, Fbg abnormal(PT&gt;16s,APTT&gt;43s,TT&gt;21s,Fbg&lt;2g/L), or have hemorrhagic tendency or receiving the therapy of thrombolysis or anticoagulation Active peptic ulcer Previously medication include sunitinib More than 4 weeks since the last clinical trial Pregnant or lactating women Women of childbearing age do not take effective contraceptive measures Allergies, or known allergy history to components of the drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Famitinib</keyword>
	<keyword>Advanced Solid tumor</keyword>
	<keyword>Phase I</keyword>
</DOC>